v3.25.2
Nature of Business (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 22, 2025
USD ($)
$ / shares
Jun. 30, 2025
USD ($)
$ / shares
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
$ / shares
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
$ / shares
Jul. 31, 2024
$ / shares
Resale Agreement Counterparty [Line Items]                  
Number of operating segments | segment           1      
Net loss   $ 14,739 $ 15,350 $ 15,280 $ 11,924 $ 30,089 $ 27,204    
Accumulated deficit   370,310       370,310   $ 340,221  
Cash   $ 27,013   $ 15,697   $ 27,013 $ 15,697 $ 58,514  
Common stock, par value (in USD per share) | $ / shares   $ 0.01       $ 0.01   $ 0.01 $ 0.01
Contemplated private financing $ 25,000                
Expected ownership percentage 50.00%                
OrthoCellix                  
Resale Agreement Counterparty [Line Items]                  
Common stock, par value (in USD per share) | $ / shares $ 0.00001                
Carisma                  
Resale Agreement Counterparty [Line Items]                  
Common stock, par value (in USD per share) | $ / shares $ 0.001                
Private financing share issuance amount $ 5,000